Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Intravenous (IV) Ulimorelin Administered Post-Operatively to Accelerate Recovery of Gastrointestinal (GI) Motility in Subjects Who Have Undergone Partial Bowel Resection
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Dec 2014
Price :
$35
*
At a glance
- Drugs Ulimorelin (Primary)
- Indications Gastrointestinal motility disorders
- Focus Therapeutic Use
- Sponsors Ocera Therapeutics
- 08 Dec 2014 New trial record